Brief: Ampio Pharmaceuticals Inc - More Than 350 Patients Have Now Reached AP-013 Study's 12-Week Primary Endpoint

Ampio Pharmaceuticals

04/12/2019 14:13

Ampio Pharmaceuticals Inc  AMPE.A :
    * AMPIO PROVIDES UPDATE ON AP-013 PHASE III CLINICAL TRIAL
AND
ANNUAL MEETING CONFERENCE CALL NUMBER
    * AMPIO PHARMACEUTICALS INC - AS OF DECEMBER 3, 2019, OF
1,034
PATIENTS TO BE ENROLLED IN AP-013
    * AMPIO PHARMACEUTICALS INC - MORE THAN 350 PATIENTS HAVE
NOW
REACHED AP-013 STUDY'S 12-WEEK PRIMARY ENDPOINT
    * AMPIO PHARMA - ON OCTOBER 22, INDEPENDENT SAFETY
MONITORING
COMMITTEE COMPLETED A CONFIDENTIAL REVIEW OF RESULTS FROM FIRST
300 RANDOMIZED SUBJECTS
    * AMPIO PHARMACEUTICALS INC - AS A RESULT OF REVIEW, CURRENT
SAFETY PROFILES OF AMPION AND PLACEBO INJECTIONS ARE SIMILAR
    * AMPIO PHARMACEUTICALS INC - STUDY INVESTIGATORS HAVE
IDENTIFIED
NO REMARKABLE SAFETY FINDINGS

Source text for Eikon:  ID:nPn8tYMFfa 
Further company coverage:  AMPE.A